UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000012232
Receipt number R000014129
Scientific Title A study of eribulin in combination with trastuzumab and pertuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer
Date of disclosure of the study information 2013/11/07
Last modified on 2021/07/15 15:45:33

No. Disposal Last modified on Item of update
1 Insert 2013/11/07 16:12:43
2 Update 2013/12/06 13:47:07 Recruitment status
3 Update 2014/05/09 15:45:48 Institutions
4 Update 2014/06/10 10:40:43 Institutions
5 Update 2014/11/07 10:37:32 Address
Address
TEL
Address
Address
TEL
Institutions
6 Update 2014/12/10 11:28:10 Institutions
7 Update 2015/05/07 09:49:19 Institutions
8 Update 2015/11/09 13:25:48 Last follow-up date
9 Update 2015/12/08 15:18:29 Institutions
10 Update 2016/05/09 09:10:20 Name of primary person or sponsor
Organization
11 Update 2016/07/08 15:30:43 Recruitment status
12 Update 2017/05/11 11:18:11 Organization
Organization
Division name
Division name
Address
Address
TEL
Email
13 Update 2018/08/23 17:42:25 Public title
14 Update 2018/08/24 10:09:25 UMIN ID1
15 Update 2019/03/28 16:26:03 Date of IRB
16 Update 2019/09/05 15:01:01 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address
Address

Last name of contact person

Last name of contact person
Zip code
Address
Address
Organization
Organization
Address
Address
Tel
Email
17 Update 2019/09/05 15:02:20 Number of participants that the trial has enrolled
18 Update 2021/07/09 11:59:02
Last name of contact person

Last name of contact person
Name of person sending information
Name of person sending information
19 Update 2021/07/15 15:45:33 Homepage URL